I agree that this site is using cookies. You can find further informations here.
X
Bachelot, Thomas
506  results:
Search for persons X
?
1

Trastuzumab deruxtecan in previously treated HER2‐positive ..:

Petit, Thierry ; Hajjaji, Nawale ; Antoine, Eric‐Charles...
Cancer Medicine.  13 (2024)  9 - p. , 2024
Link: https://doi.org/10.1002/..
 
?
2

Long-term response to sequential anti-HER2 therapies includ..:

de Bernardi, Axel ; Bachelot, Thomas ; Larrouquère, Louis
Frontiers in Oncology.  13 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
3

Association between endocrine adjuvant therapy intake timin..:

Giacchetti, Sylvie ; Laas, Enora ; Bachelot, Thomas...
eBioMedicine.  104 (2024)  - p. 105141 , 2024
Link: https://doi.org/10.1016/..
 
?
4

p4EBP1 staining predicts outcome in ER-positive endocrine-r..:

Vanacker, Hélène ; Treilleux, Isabelle ; Schiffler, Camille...
British Journal of Cancer.  130 (2024)  4 - p. 613-619 , 2024
Link: https://doi.org/10.1038/..
 
?
5

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2..:

Cortés, Javier ; Hurvitz, Sara A. ; Im, Seock-Ah...
Nature Medicine.  , 2024
Link: https://doi.org/10.1038/..
 
?
6

First-line real-world treatment patterns and survival outco..:

Galvin, Angéline ; Courtinard, Coralie ; Bouteiller, Fanny...
European Journal of Cancer.  196 (2024)  - p. 113422 , 2024
Link: https://doi.org/10.1016/..
 
?
7

Trastuzumab deruxtecan in metastatic breast cancer with var..:

Mosele, Fernanda ; Deluche, Elise ; Lusque, Amelie...
Nature Medicine.  29 (2023)  8 - p. 2110-2120 , 2023
Link: https://doi.org/10.1038/..
 
?
8

CHEOPS trial: a GINECO group randomized phase II assessing ..:

Bailleux, Caroline ; Arnaud, Antoine ; Frenel, Jean-Sébastien...
Breast Cancer.  30 (2023)  2 - p. 315-328 , 2023
Link: https://doi.org/10.1007/..
 
?
9

Long-Term Results with Everolimus in Advanced Hormone Recep..:

François-Martin, Hélène ; Lardy-Cléaud, Audrey ; Pistilli, Barbara...
Cancers.  15 (2023)  4 - p. 1191 , 2023
Link: https://doi.org/10.3390/..
 
?
10

Insights adjusting for non-adherence in randomized clinical..:

Giudici, Fabiola ; Pistilli, Barbara ; Vaz-Luis, Ines...
British Journal of Cancer.  129 (2023)  9 - p. 1516-1523 , 2023
Link: https://doi.org/10.1038/..
 
?
11

Real-World Impact of Adjuvant Anti-HER2 Treatment on Charac..:

Le Du, Fanny ; Carton, Matthieu ; Bachelot, Thomas...
The Oncologist.  28 (2023)  10 - p. e867-e876 , 2023
Link: https://doi.org/10.1093/..
 
?
12

Association of chemotherapy and comorbidities with overall ..:

Corbaux, Pauline ; Terret, Catherine ; Cropet, Claire...
International Journal of Clinical Oncology.  28 (2023)  3 - p. 371-381 , 2023
Link: https://doi.org/10.1007/..
 
?
13

TROPION-Breast02: Datopotamab deruxtecan for locally recurr..:

Dent, Rebecca A ; Cescon, David W ; Bachelot, Thomas...
Future Oncology.  19 (2023)  35 - p. 2349-2359 , 2023
Link: https://doi.org/10.2217/..
 
?
14

Clinical outcome of patients with isolated central nervous ..:

Collet, Laetitia ; Eberst, Lauriane ; Ludovic, Gauthier...
Breast Cancer.  30 (2023)  2 - p. 329-341 , 2023
Link: https://doi.org/10.1007/..
 
?
15

Rs867228 in FPR1 accelerates the manifestation of luminal B..:

Carbonnier, Vincent ; Le Naour, Julie ; Bachelot, Thomas...
OncoImmunology.  12 (2023)  1 - p. , 2023
Link: https://doi.org/10.1080/..
 
1-15